Goldman Sachs Sell Call on Novartis Amid Rising Generic Competition

about 1 month ago

Sam Unstead

"Goldman Sachs cut Novartis to sell today. They basically said that the last few years, Novartis has been on a good run, but over the next couple of years structural shifts and increased generic competition could drag down its growth."

Goldman Sachs has downgraded Novartis to a sell rating. The downgrade is based on the expectation that rising competition from generics will erode Novartis' growth in the coming years, which poses a risk for investors. This presents an actionable signal to consider reducing exposure to Novartis (ticker NVS).

Related Stocks